Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis

Abstract

done with resected specimens to examine the expression level of chemokine receptor CCR7 in cancer cells and elucidate whether the expression level is associated with lymph node metastasis. CCR7 staining was evaluated by visual assessment. Results: The membrane of distal bile duct cancer cells were heterogeneously immunostained by antibody for CCR7. 18 of 34 cases were positive for CCR7 expression (53%). 17 of 18 cases with lymph node metastasis were positive whereas 9 of 16 cases without lymph node metastasis were positive (p = 0.0019 by Fisher's exact test). When the staining level was categorized into 3 groups as negative, moderately positive and strongly positive (1, 4 and 13 patients with LN metastasis, and 9, 6 and 1 without, respectively) the statistical difference expanded (p = 0.000029 by Manne Whitney U test). Conclusion:The expression level of CCR7 in distal bile duct cancer cells could be one of the factors that promote lymph node metastasis.

Impact of microvascular invasion on clinical outcomes after curative‐intent resection for intrahepatic cholangiocarcinoma

“…To this point, several studies have reported that liver‐directed therapy for recurrences, such as surgical resection, transarterial chemoembolization, and radiofrequency ablation, might improve the prognosis of patients with recurrent ICC . In addition, although the effect of adjuvant chemotherapy on the prognosis of ICC patients remains debatable, several studies have demonstrated potential survival benefits of adjuvant chemotherapy among “high‐risk” patients with advanced tumor characteristics, such as nodal metastasis, advanced stages, or an inadequate margin . As such, patients with MiVI should similarly be considered for appropriate adjuvant therapy.…”

The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis

“…Using a random-effect model, the pooled HR for the OS in the AT group was 0.60 (95%CI 0.51~0.69, Fig 6A), compared with the non-AT group. The effect of AT on the patients with LNM was evaluated in 4 included cohorts [9,16,24,26]. Using a random-effect model, the pooled HR for the OS in the AT group was 0.67 (95%CI 0.57~0.76, Fig 6B), compared with the non-AT group.…”

“…Various kinds of adjuvant therapies (AT), such as chemotherapy [8][9][10], radiotherapy [11,12], transarterial chemoembolization (TACE) [13,14], and chemoradiotherapy [15] have been conducted prevalently to improve the prognosis of patients after resection, and 21.4%-57.7% of patients were reported to receive AT after resection [14,16]. However, the benefit of AT remains controversial [8,9,12]. Considering that randomized controlled trials or prospective studies evaluating the clinical vale of AT are hard to conduct, a comprehensive systematic review and meta-analysis is needed to confirm it.…”

Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study

“…Recently, AT, such as transarterial chemoembolization (TACE), chemotherapy, radiotherapy, and comprehensive treatment, has been conducted prevalently worldwide to improve ICC patient prognosis after radical resection . However, there is still controversy over whether ICC patients can benefit from AT after radical resection .…”